Z-YVAD-FMK: Benchmark Caspase-1 Inhibitor for Inflammation Studies

Executive Summary: Z-YVAD-FMK (CAS 210344-97-1) is a highly selective, irreversible inhibitor of caspase-1, a cysteine protease mediating inflammation and pyroptotic cell death. The compound covalently modifies the caspase-1 active site, blocking downstream IL-1β and IL-18 secretion with minimal off-target effects on other caspases, such as caspase-3, at recommended concentrations [product_spec: https://www.apexbt.com/z-yvad-fmk.html]. It demonstrates efficacy in both cell-based and animal models, notably reducing butyrate-induced apoptosis in Caco-2 colon carcinoma cells at 100 μmol/L [paper: https://doi.org/10.33594/000000601]. Z-YVAD-FMK is cell-permeable, soluble at ≥31.55 mg/mL in DMSO, and supplied by APExBIO as the A8955 kit for research on apoptosis, pyroptosis, and inflammasome signaling. Proper solubilization and storage conditions are required for consistent experimental outcomes [product_spec].

Biological Rationale

Caspase-1 is a critical cysteine protease responsible for the maturation of pro-inflammatory cytokines IL-1β and IL-18, as well as the induction of pyroptotic cell death in response to inflammasome activation [paper: https://doi.org/10.33594/000000601]. Excessive or dysregulated caspase-1 activation is implicated in diverse pathological processes, including acute lung injury, septic shock, and cancer. Targeting caspase-1 provides a strategy to modulate inflammatory signaling and cell death without broadly suppressing apoptosis or necroptosis pathways. Z-YVAD-FMK offers a means to dissect these pathways with high specificity, facilitating mechanistic studies across inflammation, cancer research, and cell death biology.

Mechanism of Action of Z-YVAD-FMK

Z-YVAD-FMK is a synthetic peptide analog with an N-terminal benzyloxycarbonyl (Z) group and a fluoromethyl ketone (FMK) at the C-terminus. The YVAD motif mimics the substrate recognition sequence of caspase-1. Upon cell entry, the FMK moiety forms a covalent bond with the active site cysteine of caspase-1, irreversibly inhibiting its proteolytic activity [product_spec: https://www.apexbt.com/z-yvad-fmk.html]. This inhibition prevents the cleavage of pro-IL-1β and pro-IL-18, blocking their maturation and secretion. Z-YVAD-FMK's cell-permeability results from the Z-protecting group, facilitating access to intracellular caspase-1. Its selectivity profile is characterized by negligible inhibition of closely related caspases, such as caspase-3, under recommended concentrations [product_spec].

Evidence & Benchmarks

• Z-YVAD-FMK at 100 μmol/L significantly attenuates butyrate-induced apoptosis and growth inhibition in Caco-2 colon carcinoma cells [paper: https://doi.org/10.33594/000000601].
• Intravenous administration in animal models selectively reduces caspase-1 activity in retinal tissues without affecting caspase-3, confirming specificity in vivo [product_spec: https://www.apexbt.com/z-yvad-fmk.html].
• Z-YVAD-FMK blocks IL-1β and IL-18 release downstream of inflammasome activation, enabling precise modulation of inflammatory cytokine output [product_spec: https://www.apexbt.com/z-yvad-fmk.html].
• In cell death studies, pan-caspase inhibitors such as zVAD-fmk, structurally related to Z-YVAD-FMK, abrogate caspase-dependent apoptosis but not cathepsin-mediated or necroptotic death, demonstrating the importance of pathway-selective tools [paper: https://doi.org/10.33594/000000601].

For a mechanistic and workflow-focused comparison, see this guide, which details best practices and advanced applications. This article extends those findings by emphasizing direct quantitative benchmarks and selectivity data.

Applications, Limits & Misconceptions

Z-YVAD-FMK, supplied by APExBIO, is widely used in:

• Apoptosis assay workflows to differentiate caspase-1-dependent from independent cell death [product_spec].
• Pyroptosis research to dissect inflammasome pathway contributions in immune cells and cancer models [https://caspbio.com/index.php?g=Wap&m=Article&a=detail&id=11347]. This article provides updated data on solubility and in vivo selectivity.
• Inflammasome activation studies, particularly in cytokine-driven disease models.
• Cancer research exploring caspase-1 roles in tumor cell death and immune modulation.

However, the inhibitor does not block cathepsin-dependent or necroptosis pathways, as these proceed independently of caspase-1 [paper: https://doi.org/10.33594/000000601].

Common Pitfalls or Misconceptions

• Non-selectivity: Z-YVAD-FMK does not broadly inhibit all caspases; it is highly selective for caspase-1 at recommended doses [product_spec].
• Solubility errors: The compound is insoluble in water and ethanol; DMSO (≥31.55 mg/mL) is required for stock solutions; warming and ultrasonic treatment may be necessary [product_spec].
• Inappropriate storage: Stock solutions should be kept at -20°C and used promptly to avoid hydrolysis and loss of potency [product_spec].
• Non-applicability to cathepsin-dependent or necroptosis pathways: Z-YVAD-FMK fails to inhibit cell death mediated by these routes [paper: https://doi.org/10.33594/000000601].

Workflow Integration & Parameters

For best results, researchers should use Z-YVAD-FMK as follows:

Protocol Parameters

• apoptosis assay | 100 μmol/L | Caco-2 colon cancer cells | Inhibits butyrate-induced apoptosis | paper: https://doi.org/10.33594/000000601
• pyroptosis research | 10–100 μmol/L | immune cell models | Blocks caspase-1-dependent cytokine release | workflow_recommendation
• solubility check | ≥31.55 mg/mL (DMSO) | stock preparation | Ensures maximal solubility for experimental use | product_spec: https://www.apexbt.com/z-yvad-fmk.html
• storage | -20°C | all research applications | Prevents degradation and hydrolysis | product_spec
• shipping | blue ice | small molecule transport | Preserves compound integrity during transit | product_spec

For detailed experimental optimization and troubleshooting, see the workflow-centric guide (which this article updates by adding new selectivity data), and this high-specificity review for further context.

Conclusion & Outlook

Z-YVAD-FMK remains the benchmark irreversible caspase-1 inhibitor for dissecting inflammasome signaling and cell death mechanisms in vitro and in vivo. Its proven selectivity profile and robust performance in apoptosis and pyroptosis research have cemented its role in experimental immunology and cancer biology [product_spec, https://doi.org/10.33594/000000601]. Future studies will expand upon its use in disease models characterized by dysregulated inflammasome activity, but its current application is best suited for mechanistic studies requiring precise modulation of caspase-1 activity. For further technical details and product specifications, visit the APExBIO product page.